Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Food Labeling; Notification Procedures for Statements on Dietary Supplements, 25282-25283 [2019-11419]
Download as PDF
25282
Federal Register / Vol. 84, No. 105 / Friday, May 31, 2019 / Notices
events/improving-implementation-riskbased-monitoring-approaches-clinicaltrials.
Transcripts: Please be advised that
transcripts of the public workshop will
not be available.
Dated: May 28, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–11411 Filed 5–30–19; 8:45 am]
BILLING CODE 4164–01–P
Food and Drug Administration
[Docket No. FDA–2013–N–0032]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Food Labeling;
Notification Procedures for Statements
on Dietary Supplements
Food and Drug Administration,
HHS.
ACTION:
Domini Bean, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–5733, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Food Labeling; Notification Procedures
for Statements on Dietary
Supplements—21 CFR 101.93
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
FOR FURTHER INFORMATION CONTACT:
Notice.
The Food and Drug
Administration (FDA or we) is
announcing that a proposed collection
of information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by July 1,
2019.
SUMMARY:
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, Fax: 202–
395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0331. Also
include the FDA docket number found
in brackets in the heading of this
document.
ADDRESSES:
OMB Control Number 0910–0331—
Extension
Section 403(r)(6) of the Federal Food,
Drug, and Cosmetic Act (FD&C Act) (21
U.S.C. 343(r)(6)) and § 101.93 (21 CFR
101.93) of our regulations require that,
no later than 30 days after the first
marketing, we be notified by the
manufacturer, packer, or distributor of a
dietary supplement that it is marketing
a dietary supplement product that bears
on its label or in its labeling a statement
provided for in section 403(r)(6) of the
FD&C Act. In accordance with these
requirements, submissions must
include: (1) The name and address of
the manufacturer, packer, or distributor
of the dietary supplement product; (2)
the text of the statement that is being
made; (3) the name of the dietary
ingredient or supplement that is the
subject of the statement; (4) the name of
the dietary supplement (including the
brand name); and (5) the signature of a
responsible individual or the person
who can certify the accuracy of the
information presented, and who must
certify that the information contained in
the notice is complete and accurate, and
that the notifying firm has
substantiation that the statement is
truthful and not misleading.
Our electronic form (Form FDA 3955)
allows respondents to the information
collection to electronically submit
notifications to FDA via an electronic
system. We are upgrading our current
system (the FDA Unified Registration
Listing System known as FURLS) to
deploy the Food Applications
Regulatory Management (FARM)
system. FARM is modeled after FURLS
and collects the same information, but
improves our operational efficiency. A
web link of the FARM system can be
found here: https://www.fda.gov/Food/
DietarySupplements/IndustryInfo/
ucm485532.htm. Firms that prefer to
submit a paper notification in a format
of their own choosing still have the
option to do so; however, Form FDA
3955 prompts respondents to include
certain elements in their structure/
function claim notification (SFCN)
described in § 101.93 in a standard
electronic format and helps respondents
organize their SFCN to include only the
information needed for our review of
the claim. Note that the SFCN, whether
electronic or paper, is used for all
claims made pursuant to section
403(r)(6) of the FD&C Act, including
nutrient deficiency claims and general
well-being claims in addition to
structure/function claims. The
electronic form, and any optional
elements prepared as attachments to the
form (e.g., label), can be submitted in
electronic format. Submissions of
SFCNs will continue to be allowed in
paper format. We use this information to
evaluate whether statements made for
dietary ingredients or dietary
supplements are permissible under
section 403(r)(6) of the FD&C Act.
In the Federal Register of February 7,
2019 (84 FR 2528), we published a 60day notice requesting public comment
on the proposed collection of
information. No comments were
received.
Description of Respondents:
Respondents to this collection of
information include manufacturers,
packers, or distributors of dietary
supplements that bear section 403(r)(6)
of the FD&C Act statements on their
labels or labeling.
We estimate the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
khammond on DSKBBV9HB2PROD with NOTICES
101.93 ...............................................
1 There
Number of
responses per
respondent
Number of
respondents
21 CFR Section
3,690
Total annual
responses
1
3,690
Average burden per response
0.75 (45 minutes) .............................
Total hours
2,767.5
are no capital costs or operating and maintenance costs associated with this collection of information.
Our burden estimate reflects an
overall increase of 1,117.5 hours (from
1,650 hours) and a corresponding
increase of 1,490 responses (from 2,200
VerDate Sep<11>2014
16:42 May 30, 2019
Jkt 247001
responses). We attribute this adjustment
to an increase in the average number of
notification submissions we received
over the preceding 12 months, which
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
we expect will continue over the next 3
years. We believe gathering information
to satisfy the notification requirements
of section 403(r)(6) of the FD&C Act by
E:\FR\FM\31MYN1.SGM
31MYN1
Federal Register / Vol. 84, No. 105 / Friday, May 31, 2019 / Notices
submitting information regarding
section 403(r)(6) of the FD&C Act
statements on labels or in labeling of
dietary supplements imposes minimal
burden on respondents. We expect the
information needed is immediately
available to the manufacturer, packer, or
distributor of the dietary supplement
that bears such a statement on its label
or in its labeling. We believe also that
submission via the FARM system will
facilitate reporting for respondents. We
estimate that, each year, approximately
3,690 firms will submit the information
required by section 403(r)(6) of the
FD&C Act. Assuming firms require 0.75
hour to gather the information needed
and prepare a communication, we
calculate a total of 2,767.5 hours (3,690
total annual responses × 0.75 hour).
Notice; establishment of a
public docket; request for comments.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
The Food and Drug
Administration (FDA or the Agency) is
announcing the establishment of a
docket to solicit public comment on a
potential modification to the Opioid
Analgesic Risk Evaluation and
Mitigation Strategy (OA REMS) to
require that certain solid, oral dosage
forms of immediate-release (IR) opioid
analgesics commonly prescribed for
treatment of acute pain be made
available in fixed-quantity unit-of-use
blister packaging for outpatient
dispensing. This could reduce the
amount of unused opioid analgesics,
thereby reducing opportunities for
misuse, abuse, inappropriate access, and
overdose, and possibly reducing the
development of new opioid addiction.
DATES: Submit either electronic or
written comments by July 30, 2019.
ADDRESSES: You may submit comments
as follows. Please note that late,
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2019–N–1845 for ‘‘Fixed-Quantity Unitof-Use Blister Packaging for Certain
Immediate-Release Opioid Analgesics
for Treatment of Acute Pain;
Establishment of a Public Docket;
Request for Comments.’’ Received
Dated: May 28, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–11419 Filed 5–30–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–N–1845]
Fixed-Quantity Unit-of-Use Blister
Packaging for Certain ImmediateRelease Opioid Analgesics for
Treatment of Acute Pain;
Establishment of a Public Docket;
Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
SUMMARY:
khammond on DSKBBV9HB2PROD with NOTICES
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before July 30, 2019.
The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of July 30, 2019. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
VerDate Sep<11>2014
16:42 May 30, 2019
Jkt 247001
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
25283
comments, those filed in a timely
manner (see ADDRESSES), will be placed
in the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Patrick Raulerson, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6260,
Silver Spring, MD 20993, 301–796–
3522, Patrick.Raulerson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
In 2017, opioid-involved overdoses
killed more than 47,000 people, with
E:\FR\FM\31MYN1.SGM
31MYN1
Agencies
[Federal Register Volume 84, Number 105 (Friday, May 31, 2019)]
[Notices]
[Pages 25282-25283]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-11419]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-0032]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Food Labeling;
Notification Procedures for Statements on Dietary Supplements
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is announcing
that a proposed collection of information has been submitted to the
Office of Management and Budget (OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by July 1,
2019.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
Fax: 202-395-7285, or emailed to [email protected]. All
comments should be identified with the OMB control number 0910-0331.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-5733,
[email protected].
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Food Labeling; Notification Procedures for Statements on Dietary
Supplements--21 CFR 101.93
OMB Control Number 0910-0331--Extension
Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act (FD&C
Act) (21 U.S.C. 343(r)(6)) and Sec. 101.93 (21 CFR 101.93) of our
regulations require that, no later than 30 days after the first
marketing, we be notified by the manufacturer, packer, or distributor
of a dietary supplement that it is marketing a dietary supplement
product that bears on its label or in its labeling a statement provided
for in section 403(r)(6) of the FD&C Act. In accordance with these
requirements, submissions must include: (1) The name and address of the
manufacturer, packer, or distributor of the dietary supplement product;
(2) the text of the statement that is being made; (3) the name of the
dietary ingredient or supplement that is the subject of the statement;
(4) the name of the dietary supplement (including the brand name); and
(5) the signature of a responsible individual or the person who can
certify the accuracy of the information presented, and who must certify
that the information contained in the notice is complete and accurate,
and that the notifying firm has substantiation that the statement is
truthful and not misleading.
Our electronic form (Form FDA 3955) allows respondents to the
information collection to electronically submit notifications to FDA
via an electronic system. We are upgrading our current system (the FDA
Unified Registration Listing System known as FURLS) to deploy the Food
Applications Regulatory Management (FARM) system. FARM is modeled after
FURLS and collects the same information, but improves our operational
efficiency. A web link of the FARM system can be found here: https://www.fda.gov/Food/DietarySupplements/IndustryInfo/ucm485532.htm. Firms
that prefer to submit a paper notification in a format of their own
choosing still have the option to do so; however, Form FDA 3955 prompts
respondents to include certain elements in their structure/function
claim notification (SFCN) described in Sec. 101.93 in a standard
electronic format and helps respondents organize their SFCN to include
only the information needed for our review of the claim. Note that the
SFCN, whether electronic or paper, is used for all claims made pursuant
to section 403(r)(6) of the FD&C Act, including nutrient deficiency
claims and general well-being claims in addition to structure/function
claims. The electronic form, and any optional elements prepared as
attachments to the form (e.g., label), can be submitted in electronic
format. Submissions of SFCNs will continue to be allowed in paper
format. We use this information to evaluate whether statements made for
dietary ingredients or dietary supplements are permissible under
section 403(r)(6) of the FD&C Act.
In the Federal Register of February 7, 2019 (84 FR 2528), we
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
Description of Respondents: Respondents to this collection of
information include manufacturers, packers, or distributors of dietary
supplements that bear section 403(r)(6) of the FD&C Act statements on
their labels or labeling.
We estimate the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden 1
----------------------------------------------------------------------------------------------------------------
Number of
21 CFR Section Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
101.93........................ 3,690 1 3,690 0.75 (45 2,767.5
minutes).
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Our burden estimate reflects an overall increase of 1,117.5 hours
(from 1,650 hours) and a corresponding increase of 1,490 responses
(from 2,200 responses). We attribute this adjustment to an increase in
the average number of notification submissions we received over the
preceding 12 months, which we expect will continue over the next 3
years. We believe gathering information to satisfy the notification
requirements of section 403(r)(6) of the FD&C Act by
[[Page 25283]]
submitting information regarding section 403(r)(6) of the FD&C Act
statements on labels or in labeling of dietary supplements imposes
minimal burden on respondents. We expect the information needed is
immediately available to the manufacturer, packer, or distributor of
the dietary supplement that bears such a statement on its label or in
its labeling. We believe also that submission via the FARM system will
facilitate reporting for respondents. We estimate that, each year,
approximately 3,690 firms will submit the information required by
section 403(r)(6) of the FD&C Act. Assuming firms require 0.75 hour to
gather the information needed and prepare a communication, we calculate
a total of 2,767.5 hours (3,690 total annual responses x 0.75 hour).
Dated: May 28, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-11419 Filed 5-30-19; 8:45 am]
BILLING CODE 4164-01-P